Related Experiment Videos
Clinical trials in diastolic heart failure
Barry M Massie1, Mary Rose Fabi
1Cardiology Division, San Francisco VAMC, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, CA, USA. barry.massie@med.va.gov
Progress in Cardiovascular Diseases
|August 24, 2005
Summary
Diastolic heart failure, affecting up to 50% of patients, often occurs in older women and lacks proven treatments. This review examines ongoing trials to improve outcomes for this understudied population.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Trials
Background:
- Diastolic heart failure (HFpEF) accounts for 40-50% of chronic heart failure cases.
- HFpEF predominantly affects older women and is characterized by preserved left ventricular ejection fraction.
- Left ventricular diastolic dysfunction is a primary driver in most HFpEF cases.
Purpose of the Study:
- To review recent and ongoing clinical trials in patients with diastolic heart failure.
- To identify potential therapeutic strategies for heart failure with preserved ejection fraction (HFpEF).
- To address the lack of evidence-based treatments for HFpEF.
Main Methods:
- Review of recent and ongoing clinical trials focused on diastolic heart failure.
- Analysis of patient populations systematically excluded from previous heart failure trials.
- Synthesis of current research trends in HFpEF treatment.
Main Results:
- Historically, patients with diastolic heart failure were excluded from major clinical trials.
- There are currently no universally proven treatments specifically for this patient group.
- Recent and ongoing trials aim to fill this evidence gap.
Conclusions:
- Diastolic heart failure represents a significant and growing clinical challenge.
- Improved understanding and treatment of HFpEF are urgently needed.
- Ongoing trials offer hope for better therapeutic options and improved patient outcomes.